HLS Therapeutics Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Public

  • Employees
  • 90

Employees

  • Stock Symbol
  • HLS

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $3.55
  • (As of Tuesday Closing)

HLS Therapeutics General Information

Description

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, and the United States, and the Rest of the world.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Distributors (Healthcare)
Stock Exchange
TSE
Corporate Office
  • 10 Carlson Court
  • Suite 701
  • Etobicoke, Ontario M9W 6L2
  • Canada
+1 (647) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

HLS Therapeutics Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.55 $3.59 $2.45 - $5.41 $114M 31.9M 10.5K -$0.85

HLS Therapeutics Financials Summary

In Thousands,
USD
TTM 31-Dec-2023 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 164,654 164,654 313,259 460,068
Revenue 63,074 63,074 61,467 60,009
EBITDA 12,534 12,534 17,940 25,368
Net Income (27,531) (27,531) (23,598) (13,117)
Total Assets 209,060 209,060 241,652 275,905
Total Debt 87,621 87,621 97,345 97,566
Public Fundamental Data provided by Morningstar, Inc. disclaimer

HLS Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore HLS Therapeutics‘s full profile, request access.

Request a free trial

HLS Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of br
Pharmaceuticals
Etobicoke, Canada
90 As of 2023
00000
000000000 00000

000 00

ure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla
000000000000000
Baudette, MN
000 As of 0000
00000
00000000 00000

00000

reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Ex
000000000000000
London, United Kingdom
0000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

HLS Therapeutics Competitors (11)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ANI Pharmaceuticals Corporation Baudette, MN 000 00000 00000000 00000
Hikma Pharmaceuticals Corporation London, United Kingdom 0000 00000 000000000 00000
Par Pharmaceutical Companies Formerly PE-Backed Ramapo, NY 0000 00.000 0000000000.
Novartis India Corporate Backed or Acquired Mumbai, India 00 00.000 0&0
Teva Pharmaceutical Industries Corporation Petah Tikva, Israel 00000 000.00 000000000 00 000.00
You’re viewing 5 of 11 competitors. Get the full list »

HLS Therapeutics Executive Team (18)

Name Title Board Seat Contact Info
John Hanna Chief Financial Officer, Finance & Board Member
John Hanna Interim Chief Financial Officer
Dawn Edinboro General Manager & Vice President
David Spence Controller, Finance & Vice President
Pauline Dapena-Cherry Director, Corporate & Business Development
You’re viewing 5 of 18 executive team members. Get the full list »

HLS Therapeutics Board Members (12)

Name Representing Role Since
00000 0000000 Self Chief Executive Officer & Board Member 000 0000
000000 00000000 HLS Therapeutics Board Member 000 0000
0000000 000000 HLS Therapeutics Co-Founder, Director & Chairman 000 0000
0. 00000000 HLS Therapeutics Board Member 000 0000
0000 00000 HLS Therapeutics Chief Financial Officer, Finance & Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

HLS Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

HLS Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore HLS Therapeutics‘s full profile, request access.

Request a free trial

HLS Therapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Automodular 12-Mar-2018 0000000000 000.00 Other Financial Services 0000000 0
To view HLS Therapeutics’s complete acquisitions history, request access »

HLS Therapeutics ESG

Risk Overview

Risk Rating

Updated April, 01, 2022

44.42 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

0.000

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,480

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 905

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 435

Rank

00.00

Percentile

To view HLS Therapeutics’s complete esg history, request access »

HLS Therapeutics FAQs

  • When was HLS Therapeutics founded?

    HLS Therapeutics was founded in 2018.

  • Who is the founder of HLS Therapeutics?

    Gilbert Godin is the founder of HLS Therapeutics.

  • Who is the CEO of HLS Therapeutics?

    Craig Millian is the CEO of HLS Therapeutics.

  • Where is HLS Therapeutics headquartered?

    HLS Therapeutics is headquartered in Etobicoke, Canada.

  • What is the size of HLS Therapeutics?

    HLS Therapeutics has 90 total employees.

  • What industry is HLS Therapeutics in?

    HLS Therapeutics’s primary industry is Pharmaceuticals.

  • Is HLS Therapeutics a private or public company?

    HLS Therapeutics is a Public company.

  • What is HLS Therapeutics’s stock symbol?

    The ticker symbol for HLS Therapeutics is HLS.

  • What is the current stock price of HLS Therapeutics?

    As of 16-Apr-2024 the stock price of HLS Therapeutics is $3.55.

  • What is the current market cap of HLS Therapeutics?

    The current market capitalization of HLS Therapeutics is $114M.

  • What is HLS Therapeutics’s current revenue?

    The trailing twelve month revenue for HLS Therapeutics is $63.1M.

  • Who are HLS Therapeutics’s competitors?

    ANI Pharmaceuticals, Hikma Pharmaceuticals, Par Pharmaceutical Companies, Novartis India, and Teva Pharmaceutical Industries are some of the 11 competitors of HLS Therapeutics.

  • What is HLS Therapeutics’s annual earnings per share (EPS)?

    HLS Therapeutics’s EPS for 12 months was -$0.85.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »